Generation of a P4hb(Y393C) mouse model of cole-carpenter syndrome and therapeutic proof-of-concept.
First disease model for ultra-rare bone disorder identified two druggable pathways ready for near-term clinical testing.
Cole-Carpenter syndrome is an ultra-rare autosomal dominant skeletal disorder caused by P4HB mutations with no disease-modifying treatment. This study generated the first mouse model carrying the recurrent Y393C mutation, confirmed its pathogenic mechanisms, then used an FDA-approved drug screen and allele-specific siRNA to identify two promising therapeutic approaches for near-term translational development.
What the study was
- Study design
- preclinical_disease_model
- Category
- rare_diseases
- Maturity
- Exploratory
- Journal
- Life Sci
Why it surfaced
Addresses a currently untreatable ultra-rare disorder; dual therapeutic readout (drug repurposing + siRNA) increases translational value; design_quality and clinical_applicability capped as preclinical mouse model study; Life Sci is a moderate-impact journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.